publication date: Jan. 4, 2019

NCI Trials

NCI Trials for January

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

 

Phase I 10184

Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

National Cancer Institute LAO

Saloura, Vassiliki

(301) 594-0911

 

Phase I 10219

Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Mayo Clinic Cancer Center LAO

Gonsalves, Wilson I.

(507) 266-0792

 

Phase II LUNGMAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

SWOG

Papadimitrakopoulou, Vassiliki A.

(713) 792-6363

 

Phase II S1801

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

SWOG

Patel, Sapna Pradyuman

(713) 792-2921

 

Phase II/III EA2174

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

ECOG-ACRIN Cancer Research Group

Eads, Jennifer Rachel

(215) 615-1725

 

Phase III A041702

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of … Continue reading NCI Trials for January 2019

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.